- Alta Partners, a San Francisco, CA and Denver, CO-based early-stage healthcare venture capital firm, closed Alta Partners NextGen Fund III, L.P., at $275m
- The firm’s limited partners include some of the leading healthcare organizations in the nation, top financial investors, and successful family offices
- Alta has raised over $2.3 billion in venture funds, launched over 70 new drugs, and delivered 118 exits and IPOs creating over $36 billion in value for partners
- The firm raised NextGen Fund I in 2017, and Fund II in 2019 both funds focusing on a concentrated portfolio of companies working with an outstanding group of entrepreneurs
- In the four years since Fund I closed, the portfolio of early-stage companies invested in by the fund have grown into over $19 billion in enterprise value
- Alta has invested in some leading biotech therapeutics companies, also including Allakos, VIR Biotechnology, BeBiopharma, and TYRA Biosciences
